Day 2Thursday, 24 April 2025 - CT (China Time, GMT+08:00)

Location: Pudong Ballroom 1-3

Location: Pudong Ballroom 1-3

In a competitive biotech environment, newly formed companies (Newcos) have the potential to disrupt the landscape with innovative solutions, but they also face unique challenges in securing investment and achieving growth. This panel will bring together investors, biotech executives, and industry experts to discuss how Newcos can strategically position themselves to attract attention and capitalize on opportunities within the global and Chinese biotech ecosystems.

• What differentiates successful Newcos from the rest, and how can they craft compelling value propositions that resonate with investors across various regions, including China, APAC, and beyond?

• Exploring the essential elements of a strong foundation for Newcos, including partnerships, talent acquisition, and technology platforms that can drive long-term success.

• Insights into how Newcos can tailor their strategies to align with specific market conditions in different parts of the world, focusing on China's rapidly evolving biotech landscape.

Location: Pudong Ballroom 1-3

Join us for a dynamic fireside chat with a senior executive from a leading multinational corporation as we uncover the secrets to getting your biotech noticed. This conversation will dive into what MNCs look for when considering acquisitions or licensing deals, highlighting the game-changing role of clinical data, innovation, and strategic positioning. Get insider tips on how to make your biotech stand out and become a must-have in the competitive market. 

• The power of solid clinical data, cutting-edge technology, and a compelling value proposition in capturing MNC interest. 

• Expert advice on positioning your biotech to rise above the competition and secure lucrative partnerships or acquisitions.

Location: Pudong Ballroom 1-3

This panel will delve into how the convergence of AI and big data is reshaping the landscape of drug discovery and development, offering unprecedented opportunities for efficiency and innovation. Industry experts, data scientists, and biotech leaders will discuss how these technologies are not only transforming traditional research methodologies but also addressing challenges in experimental data reliability and integration into broader innovation strategies. The conversation will focus on the implications for accelerating drug development, cost reduction, and fostering collaboration among global firms.

• How are AI and big data fundamentally changing drug discovery processes, and what competitive advantages do they provide in speeding up R&D in China and globally?

• What are the critical challenges in ensuring the reliability of experimental data for AI model training as companies leverage AI for rapid drug design? How can addressing these challenges enhance cost reduction across the drug development lifecycle, and which specific areas within drug development are particularly suited for applied AI to maximize efficiency?